Diabetes management company Welldoc is teaming up with Eli Lilly on a new licensing and collaboration agreement that promises to integrate the former’s software into the pharma company’s insulin products, which are still in the pipeline.
The partners plan on creating a new version of Welldoc’s BlueStar, an app-based diabetes management platform that will be able to integrate insulin dosing data...
After a year of incredible innovation across the digital health market, the task remains of how to make these products available to consumers at scale. Oftentimes, this means partnering with a payer that can offer coverage and reimbursement for the digital solution.
While making those partnerships stick is easier said than done, it is possible to get stakeholders from different spaces in...
The chronic condition management platform, Welldoc, has added a digital behavioral health program to its offerings.
The program was designed to help users develop skills to solve real-world problems in a structured way, Welldoc said in its announcement. It will be available as part of Welldoc’s platform for chronic conditions and population health management.
Users can get assistance in improving...
Bardy Diagnostics, maker of cardiac-monitoring adhesive patches, announced yesterday that Kevin Hykes began serving as the company's president and CEO on August 31. Hykes was formerly the president and CEO of Relievant Medical Systems, Metaventon and Cameron Health. Earlier in his career he spent 16 years at Medtronic. As Bardy Diagnostics' new head, he'll help develop and execute the company's...
Walgreens Boots Alliance expanded its partnership with Microsoft and Adobe to launch a digital platform that will deliver personalized healthcare and shopping offerings. It will give Walgreens and Boots customers the ability to access products and services from its pharmacy and retail businesses wherever and whenever they want. This marks WBA’s second phase of its digital transformation.
“At WBA...
WellDoc's BlueStar chronic disease-management tool has picked up another 510(k) FDA clearance that will allow it to support adult Type 2 diabetes patients using long-acting basal insulin. The feature was announced by WellDoc this morning, but cleared by the agency in April, according to a listing on its website.
The new capability takes the form of a new program within the prescription BlueStar...
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels.
“Now...
About eight month after its unveiling, Express Scripts has now revealed the companies and programs it is including in the inaugural cohort of its digital health formulary — the first such resource from a pharmacy benefits manager designed to help clients review vetted digital health programs.
The formulary is comprised of 15 clinically validated digital health programs addressing the management...
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
A half dozen digital health startups went head to head this weekend in a pitch contest hosted by the American Heart Association.
The competition’s cohort ranged from well-known heavy hitters like Welldoc to Korean hospital spinout Vuno, but in the end it was Pittsburgh-based Forest Devices that claimed top honors from both the contest’s eight judges and its audience.
“Our solution is AlphaSTROKE...
